AIMS/HYPOTHESIS: Adipose tissue (AT) distribution is a major determinant of mortality and morbidity in obesity. In mice, intra-abdominal transplantation of subcutaneous AT (SAT) protects against glucose intolerance and insulin resistance (IR), but the underlying mechanisms are not well understood. METHODS: We investigated changes in adipokines, tissue-specific glucose uptake, gene expression and systemic inflammation in male C57BL6/J mice implanted intra-abdominally with either inguinal SAT or epididymal visceral AT (VAT) and fed a high-fat diet (HFD) for up to 17 weeks. RESULTS: Glucose tolerance was improved in mice receiving SAT after 6 weeks, and this was not attributable to differences in adiposity, tissue-specific glucose uptake, or plasma leptin or adiponectin concentrations. Instead, SAT transplantation prevented HFD-induced hepatic triacylglycerol accumulation and normalised the expression of hepatic gluconeogenic enzymes. Grafted fat displayed a significant increase in glucose uptake and unexpectedly, an induction of skeletal muscle-specific gene expression. Mice receiving subcutaneous fat also displayed a marked reduction in the plasma concentrations of several proinflammatory cytokines (TNF-α, IL-17, IL-12p70, monocyte chemoattractant protein-1 [MCP-1] and macrophage inflammatory protein-1β [ΜIP-1β]), compared with sham-operated mice. Plasma IL-17 and MIP-1β concentrations were reduced from as early as 4 weeks after transplantation, and differences in plasma TNF-α and IL-17 concentrations predicted glucose tolerance and insulinaemia in the entire cohort of mice (n = 40). In contrast, mice receiving visceral fat transplants were glucose intolerant, with increased hepatic triacylglycerol content and elevated plasma IL-6 concentrations. CONCLUSIONS/ INTERPRETATION: Intra-abdominal transplantation of subcutaneous fat reverses HFD-induced glucose intolerance, hepatic triacylglycerol accumulation and systemic inflammation in mice.
AIMS/HYPOTHESIS: Adipose tissue (AT) distribution is a major determinant of mortality and morbidity in obesity. In mice, intra-abdominal transplantation of subcutaneous AT (SAT) protects against glucose intolerance and insulin resistance (IR), but the underlying mechanisms are not well understood. METHODS: We investigated changes in adipokines, tissue-specific glucose uptake, gene expression and systemic inflammation in male C57BL6/J mice implanted intra-abdominally with either inguinal SAT or epididymal visceral AT (VAT) and fed a high-fat diet (HFD) for up to 17 weeks. RESULTS:Glucose tolerance was improved in mice receiving SAT after 6 weeks, and this was not attributable to differences in adiposity, tissue-specific glucose uptake, or plasma leptin or adiponectin concentrations. Instead, SAT transplantation prevented HFD-induced hepatic triacylglycerol accumulation and normalised the expression of hepatic gluconeogenic enzymes. Grafted fat displayed a significant increase in glucose uptake and unexpectedly, an induction of skeletal muscle-specific gene expression. Mice receiving subcutaneous fat also displayed a marked reduction in the plasma concentrations of several proinflammatory cytokines (TNF-α, IL-17, IL-12p70, monocyte chemoattractant protein-1 [MCP-1] and macrophage inflammatory protein-1β [ΜIP-1β]), compared with sham-operated mice. Plasma IL-17 and MIP-1β concentrations were reduced from as early as 4 weeks after transplantation, and differences in plasma TNF-α and IL-17 concentrations predicted glucose tolerance and insulinaemia in the entire cohort of mice (n = 40). In contrast, mice receiving visceral fat transplants were glucose intolerant, with increased hepatic triacylglycerol content and elevated plasma IL-6 concentrations. CONCLUSIONS/ INTERPRETATION: Intra-abdominal transplantation of subcutaneous fat reverses HFD-induced glucose intolerance, hepatic triacylglycerol accumulation and systemic inflammation in mice.
Authors: S Caspar-Bauguil; B Cousin; A Galinier; C Segafredo; M Nibbelink; M André; L Casteilla; L Pénicaud Journal: FEBS Lett Date: 2005-07-04 Impact factor: 4.124
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Gilberto Paz-Filho; Claudio Alberto Mastronardi; Brian J Parker; Ainy Khan; Antonio Inserra; Klaus I Matthaei; Monika Ehrhart-Bornstein; Stefan Bornstein; Ma-Li Wong; Julio Licinio Journal: J Mol Endocrinol Date: 2013-06-29 Impact factor: 5.098
Authors: Darcy B Carr; Kristina M Utzschneider; Rebecca L Hull; Keiichi Kodama; Barbara M Retzlaff; John D Brunzell; Jane B Shofer; Brian E Fish; Robert H Knopp; Steven E Kahn Journal: Diabetes Date: 2004-08 Impact factor: 9.461
Authors: Miina K Ohman; Yuechun Shen; Chinyere I Obimba; Andrew P Wright; Mark Warnock; Daniel A Lawrence; Daniel T Eitzman Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: Injae Hwang; Kyuri Jo; Kyung Cheul Shin; Jong In Kim; Yul Ji; Yoon Jeong Park; Jeu Park; Yong Geun Jeon; Sojeong Ka; Sujin Suk; Hye Lim Noh; Sung Sik Choe; Assim A Alfadda; Jason K Kim; Sun Kim; Jae Bum Kim Journal: Proc Natl Acad Sci U S A Date: 2019-06-03 Impact factor: 11.205
Authors: Christopher Scott; Rebecca Stokes; Kuan Minn Cha; Andrew Clouston; Mohammed Eslam; Mayda Metwally; Michael M Swarbrick; Jacob George; Jenny E Gunton Journal: PLoS One Date: 2019-12-04 Impact factor: 3.240
Authors: Raziel Rojas-Rodriguez; Rachel Ziegler; Tiffany DeSouza; Sana Majid; Aylin S Madore; Nili Amir; Veronica A Pace; Daniel Nachreiner; David Alfego; Jomol Mathew; Katherine Leung; Tiffany A Moore Simas; Silvia Corvera Journal: Sci Transl Med Date: 2020-11-25 Impact factor: 17.956
Authors: Richard Youngblood; Carmen G Flesher; Jennifer Delproposto; Nicki A Baker; Christopher K Neeley; Fanghua Li; Carey N Lumeng; Lonnie D Shea; Robert W O'Rourke Journal: Biotechnol Bioeng Date: 2020-08-18 Impact factor: 4.530